Forvis Mazars advises on sale of Owen Mumford to US-listed Embecta

Forvis Mazars has acted as lead financial adviser to Owen Mumford on its completed sale to Embecta Corp, a US-listed diabetes care company. 

The deal, which finalised on 15 May 2026, involves an upfront cash payment of £100m, with an additional £50m in performance-based payments tied to future sales of the Aidaptus auto-injector platform.

Oxfordshire-based Owen Mumford, founded in 1952, specialises in the design and manufacture of drug delivery systems and chronic care devices. 

The acquisition provides New Jersey-based Embecta with access to a differentiated portfolio of self-injection technologies and intellectual property, supporting its transformation into a broad-based medical supplies provider.

Forvis Mazars managed the due diligence and marketing processes, drawing on its international network to solicit offers and support negotiations for the multi-generational family business.

The combined organisation will leverage Owen Mumford’s design and assembly expertise alongside Embecta’s global distribution infrastructure. 

The deal follows Embecta’s strategic separation from BD in 2022 and marks its most significant expansion into the broader obesity and autoimmune disease markets to date.

Oliver Hoffman, Deal Advisory partner at Forvis Mazars, said: “The transaction marks a significant milestone for Owen Mumford, providing the scale and global reach to support its next phase of growth. It also underscores strong overseas appetite for high-quality UK businesses and the value of our integrated international model in delivering complex cross-border deals.”

Nigel Layton, global head of Life Sciences and Pharma, added: “This transaction underlines both the resilience of the pharmaceutical and medical device sector and the ongoing demand from international buyers for UK assets. Businesses with strong intellectual property and a proven track record of innovation continue to attract significant interest – particularly from US investors.”